Single-Stranded Oligonucleotides for SMN1 and SMN2 Upregulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Amyotrophic Lateral Sclerosis (ALS) lack effective methods to upregulate Survival of Motor Neuron (SMN) protein, which is crucial for motor neuron health, as ALS progression is associated with decreased SMN activity leading to neuronal degeneration.
Innovation Solution
Administration of single-stranded oligonucleotides that target the PRC2-associated regions of the SMN1 and SMN2 genes to enhance their expression by relieving repression, thereby increasing the levels of full-length SMN protein in motor neurons, using specific sequences that are complementary to PRC2-associated regions and splice control sequences to promote spliceosome integrity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single-stranded oligonucleotides are administered to target PRC2-associated regions of SMN1 and SMN2 genes, then SMN protein expression is upregulated and motor neuron health is improved, but the complexity of the treatment protocol increases
Solution Approach 1:
The patent uses single-stranded oligonucleotides as intermediary molecules that bind to PRC2-associated regions on the SMN1 and SMN2 genes. These oligonucleotides act as mediators to disrupt the repressive interaction between PRC2 and the SMN gene promoters, thereby upregulating SMN protein expression without requiring direct manipulation of the genes themselves or complex viral delivery systems.
Solution Approach 2:
The patent replaces complex mechanical or surgical interventions with a molecular-level approach using oligonucleotide therapy. Instead of physical stimulation or invasive procedures to enhance SMN expression, the treatment uses chemically synthesized single-stranded oligonucleotides that selectively bind to regulatory regions, substituting a simple biochemical mechanism for complex physical interventions.
2Productivity
If oligonucleotides are used to target and upregulate SMN gene expression, then the effectiveness of ALS treatment is enhanced, but the manufacturing precision requirements increase
Solution Approach 1:
The patent employs specific parameter changes in oligonucleotide design, including precise control of sequence composition, length, and chemical modifications. By optimizing parameters such as GC content, melting temperature, and chemical stability, the treatment achieves high effectiveness while maintaining feasible manufacturing standards. The oligonucleotides are designed with specific sequences that complement PRC2-associated regions, ensuring targeted upregulation of SMN expression.
3Reliability
If single-stranded oligonucleotides are administered to increase SMN protein levels, then motor neuron function is improved and ALS progression is slowed, but the difficulty of delivering the treatment increases
Solution Approach 1:
The patent uses single-stranded oligonucleotides as intermediary delivery vehicles that can be administered systemically and selectively target nuclear PRC2-associated regions. These oligonucleotides serve as mediators that bridge the gap between systemic administration and nuclear gene regulation, facilitating treatment delivery without requiring direct injection into neurons or complex targeting mechanisms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively increases SMN protein expression, potentially slowing ALS progression by improving motor neuron health and function, as demonstrated by increased SMN mRNA and protein levels in treated cells and patient fibroblasts.
Implementation Method 1
single stranded oligonucleotides that target a PRC2-associated region of a SMN gene (e.g., human SMN1, human SMN2) and thereby cause upregulation of the gene
Implementation Method 2
snRNPs are protein-RNA complexes that bind with pre-mRNA to form a spliceosome, which then splices the pre-mRNA, most often resulting in removal of introns
Data Source
AI summary
Methods for modulating expression of SMN1 and/or SMN2 in cells obtained from subjects having ALS or in subjects having ALS using single stranded oligonucleotides are provided. Methods for treating ALS using single stranded oligonucleotides are also provided.